By Gardiner Harris, The Obama administration’s choice to lead the Food and Drug Administration breezed through her Senate confirmation hearing on Thursday while the administration proposed a budget that would give the agency more money
Skip to next paragraph Dr. Margaret A.
Mr. Hatch’s endorsement was followed by those of Senator Richard M. Burr, Republican of North Carolina, as well as every Democrat at the hearing of the Senate Health, Education, Labor and Pensions Committee.
One reason for the enthusiasm for Dr.
Dr. Sharfstein once worked at the advocacy organization Public Citizen and served on the staff of Representative Henry A. Waxman, a California Democrat who is a fierce critic of the drug industry.
Mr. Hatch, closely allied with drug makers, wondered aloud why the Obama administration had appointed Dr. Sharfstein and asked Dr.
“I believe that there were reports in the press that were quite misleading,” Dr.
In her opening remarks, Dr.
The committee may vote as soon as next week to send the nomination to the full Senate.
The administration proposed collecting $94 million in fees from food companies, a tax that would require Congressional approval.
The administration also proposed collecting $47 million in fees from makers of generic drugs to help finance the staff needed to reduce a backlog of years in generic drug applications. Kathleen Jaeger, president of the Generic Pharmaceutical Association, said her industry would support such fees “so long as there are guarantees that the fees would result in the timely review and approval of generic applications.”